Silence Therapeutics has been granted a patent for a method to treat cardiovascular diseases by administering nucleic acid products that inhibit the expression of the LPA gene. This approach targets conditions linked to elevated Lp(a)-containing particles, potentially reducing risks associated with coronary heart disease and stroke. GlobalData’s report on Silence Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Silence Therapeutics, was a key innovation area identified from patents. Silence Therapeutics's grant share as of July 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Nucleic acid treatment for cardiovascular disease via lpa inhibition
The granted patent US12054717B2 outlines a method for treating cardiovascular diseases, disorders, or syndromes through the administration of a specific nucleic acid or a composition containing this nucleic acid. The method focuses on inhibiting the expression of the apolipoprotein(a) (LPA) gene in cells. The nucleic acid comprises a duplex region formed by two strands: a first strand that is complementary to a portion of the RNA transcribed from the LPA gene, and a second strand that may also be complementary. The first strand is specified to be 19-35 nucleotides in length, with a defined nucleotide sequence (SEQ ID NO: 9), while the second strand ranges from 17-35 nucleotides and may include a specific sequence (SEQ ID NO: 10). The claims further detail the structural characteristics of the duplex region, including its length and the possibility of nucleotide modifications.
Additionally, the patent specifies that the method can be applied to various cardiovascular conditions, including stroke, atherosclerosis, thrombosis, coronary heart disease, and aortic stenosis. The nucleic acid may be designed with blunt ends, and it can be conjugated to a ligand, which may include N-acetyl galactosamine (GalNAc) moieties or derivatives, linked through specific chemical structures. The claims also allow for modifications to the nucleotides and provide detailed formulas for the ligands involved. Overall, the patent presents a novel approach to targeting the LPA gene expression as a therapeutic strategy for cardiovascular diseases.
To know more about GlobalData’s detailed insights on Silence Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
